Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

Graft-versus-host disease (GVHD) is a significant complication of allogeneic stem cell transplantation (alloSCT). The proteasome inhibitor bortezomib has immunomodulatory properties of potential benefit for GVHD control. We undertook a phase 1 trial of bortezomib, tacrolimus, and methotrexate for GV...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Koreth, John, Stevenson, Kristen E., Kim, Haesook T., Garcia, Michael, Ho, Vincent T., Armand, Philippe, Cutler, Corey, Ritz, Jerome, Antin, Joseph H., Soiffer, Robert J., Alyea, Edwin P.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2009
Sujets:
Transplantation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2925723/
https://ncbi.nlm.nih.gov/pubmed/19713456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-231092
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires